Dirk De Ruysscher1, Rinus Wanders2, Lizza E Hendriks3, Angela van Baardwijk2, Bart Reymen2, Ruud Houben2, Gerben Bootsma4, Cordula Pitz5, Linda van Eijsden6, Anne-Marie C Dingemans3. 1. Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl. 2. Maastro Clinic, Maastricht, The Netherlands. 3. Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 4. Department of Pulmonology, Zuyderland Hospital, Geleen, The Netherlands. 5. Department of Pulmonology, Laurentius Hospital, Roermond, The Netherlands. 6. Department of Pulmonology, Sint Jans Gasthuis, Weert, The Netherlands.
Abstract
INTRODUCTION: Two randomized studies have shown an increased progression-free survival (PFS) by adding a radical local treatment to systemic therapy in responding patients with oligometastatic NSCLC, but long-term data are lacking. We updated the results of our previous phase II trial with a minimal follow-up exceeding 7 years. METHODS: This is a prospective single-arm phase II trial. The main inclusion criteria were pathologically proven NSCLC stage IV with less than five metastases at primary diagnosis, amendable for radical local treatment (surgery or radiotherapy). No previous response to systemic treatment was needed. RESULTS: Forty patients were enrolled, 39 of whom were evaluable (18 men, 21 women); mean age was 62.1 ± 9.2 years (range, 44 to 81 years). Twenty-nine (74%) had N2 or N3 disease; 17 (44%) brain, 7 (18%) bone, and 4 (10%) adrenal gland metastases. Thirty-five (87%) had a single metastatic lesion. Thirty-seven (95%) of the patients received chemotherapy as part of their primary treatment. Median overall survival (OS) was 13.5 months (95% confidence interval: 7.6-19.4 months); 1-, 2-, 3-, 5-, and 6- year OS was 56.4%, 23.3%,12.8%, 10.3%, 7.7%, and 5.1%, respectively. Median PFS was 12.1 months (95% confidence interval: 9.6-14.3 months); 1-, 2-, 3-, 5-, and 6- year OS was 51.3%, 13.6%, %,12.8%, 7.7%, 7.7%, and 2.5%, respectively. Only three patients (7.7%) had a local recurrence. CONCLUSIONS: In patients who were not selected according to response to systemic treatment, the PFS at 5 years was 8%. Entering patients in trials combining local therapy with novel systemic agents (e.g., immunotherapy) remains mandatory.
INTRODUCTION: Two randomized studies have shown an increased progression-free survival (PFS) by adding a radical local treatment to systemic therapy in responding patients with oligometastatic NSCLC, but long-term data are lacking. We updated the results of our previous phase II trial with a minimal follow-up exceeding 7 years. METHODS: This is a prospective single-arm phase II trial. The main inclusion criteria were pathologically proven NSCLC stage IV with less than five metastases at primary diagnosis, amendable for radical local treatment (surgery or radiotherapy). No previous response to systemic treatment was needed. RESULTS: Forty patients were enrolled, 39 of whom were evaluable (18 men, 21 women); mean age was 62.1 ± 9.2 years (range, 44 to 81 years). Twenty-nine (74%) had N2 or N3 disease; 17 (44%) brain, 7 (18%) bone, and 4 (10%) adrenal gland metastases. Thirty-five (87%) had a single metastatic lesion. Thirty-seven (95%) of the patients received chemotherapy as part of their primary treatment. Median overall survival (OS) was 13.5 months (95% confidence interval: 7.6-19.4 months); 1-, 2-, 3-, 5-, and 6- year OS was 56.4%, 23.3%,12.8%, 10.3%, 7.7%, and 5.1%, respectively. Median PFS was 12.1 months (95% confidence interval: 9.6-14.3 months); 1-, 2-, 3-, 5-, and 6- year OS was 51.3%, 13.6%, %,12.8%, 7.7%, 7.7%, and 2.5%, respectively. Only three patients (7.7%) had a local recurrence. CONCLUSIONS: In patients who were not selected according to response to systemic treatment, the PFS at 5 years was 8%. Entering patients in trials combining local therapy with novel systemic agents (e.g., immunotherapy) remains mandatory.
Authors: Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh Journal: Am J Clin Oncol Date: 2021-01-01 Impact factor: 2.339
Authors: Stephanie T H Peeters; Evert J Van Limbergen; Lizza E L Hendriks; Dirk De Ruysscher Journal: Cancers (Basel) Date: 2021-04-28 Impact factor: 6.639
Authors: Jill F Mentink; Marthe S Paats; Daphne W Dumoulin; Robin Cornelissen; Joris B W Elbers; Alexander P W M Maat; Jan H von der Thüsen; Anne-Marie C Dingemans Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Johannes Uhlig; Meaghan Dendy Case; Justin D Blasberg; Daniel J Boffa; Anne Chiang; Scott N Gettinger; Hyun S Kim Journal: JAMA Netw Open Date: 2019-08-02
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27
Authors: Felipe Couñago; Javier Luna; Luis Leonardo Guerrero; Blanca Vaquero; María Cecilia Guillén-Sacoto; Teresa González-Merino; Begoña Taboada; Verónica Díaz; Belén Rubio-Viqueira; Ana Aurora Díaz-Gavela; Francisco José Marcos; Elia Del Cerro Journal: World J Clin Oncol Date: 2019-10-24